We are live on ! Find out more
SIC

Starr International Company Portfolio holdings

AUM $19.9M
1-Year Est. Return 39.69%
This Fund
S&P 500
This Quarter Est. Return
-19.73%
1 Year Est. Return
-39.69%
3 Year Est. Return
-26.08%
5 Year Est. Return
-43.79%
10 Year Est. Return
-39.24%
AUM
$59.9M
AUM Growth
+$10.1M
Cap. Flow
+$20.6M
Cap. Flow %
34.46%
Top 10 Hldgs %
100%
Holding
6
New
1
Increased
–
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
CELU icon
Celularity
CELU
+$55.2M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$25.8M
2
AZN icon
AstraZeneca
AZN
+$5.59M
3
JNJ icon
Johnson & Johnson
JNJ
+$3.23M

Sector Composition

Rank Sector Weight
1 Healthcare 73.86%
2 Financials 26.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELU icon
1
Celularity
CELU
$21.7M
$44.2M 73.86%
+864,070
New +$55.2M
BCSF icon
2
Bain Capital Specialty
BCSF
$815M
$12.1M 20.18%
794,543
– –
AIG icon
3
American International
AIG
$42B
$3.57M 5.96%
62,788
– –
AZN icon
4
AstraZeneca
AZN
$263B
– –
-46,500
Closed -$5.59M
JNJ icon
5
Johnson & Johnson
JNJ
$641B
– –
-20,000
Closed -$3.23M
MRNA icon
6
Moderna
MRNA
$22.1B
– –
-67,000
Closed -$25.8M

Similar funds

DOS
David O. Sacks $19.8M AUM 4.02% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
LUGPI
Lightspeed Ultimate General Partner IX Menlo Park, California $20.3M AUM 4.78% 1-Year Est. Return
CVSCT
C.V. Starr & Co Trust New York $19.4M AUM 28.57% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
CCFM
Cohen & Co Financial Management New York $18.3M AUM 73.48% 1-Year Est. Return
VNB
Virginia National Bank Charlottesville, Virginia $21.9M AUM 12.04% 1-Year Est. Return

Starr International Company's Q4 2021 Portfolio in Review

As of Q4 2021, Starr International Company held 6 positions worth $59.9M, up 20% from $49.8M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Starr International Company deployed $20.6M of net new capital in Q4 2021, opening 1 new position. Its largest new stake was Celularity: 864,070 shares worth $44.2M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 69% a quarter earlier, followed by Financials.

On the sell side, the most notable exit was Moderna, an estimated $25.8M sold.

  • Starr International Company's largest Q4 2021 buy was Celularity: 864,070 shares worth $44.2M.
  • Starr International Company fully exited Moderna in Q4 2021, selling an estimated $25.8M.
  • Starr International Company's ten largest holdings make up 100% of its $59.9M portfolio in Q4 2021.
  • Starr International Company opened 1 new position and closed 3 in Q4 2021.
  • Starr International Company's portfolio value rose 20% quarter-over-quarter to $59.9M.

Based on Starr International Company's 13F filing for Q4 2021, filed 27 Jan 2022.